Heart Failure

Beta-blocker treatment is beneficial in patients excluded from study

Published in Cardiovascular Week, January 30th, 2006

Beta-blocker treatment is associated with significantly reduced long-term mortality even in patients meeting one or more exclusion criteria of the MERIT-HF study.

According to a study from Germany, "Improved prognosis of patients with chronic systolic heart failure by treatment with beta-blockers has been shown in several randomized controlled multicenter trials. However, in clinical practice only a part of heart failure patients meet the inclusion criteria of these trials."

A. Jost and colleagues at Herzzentrum Ludwigshafen wrote, "The present study evaluates whether reduction of mortality by beta-blockers also can be achieved in patients presenting...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Week

Source: Cardiovascular Week (2006-01-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry